Skip to content
TickerMagic

Vimta Labs Limited

VIMTALABSNSEHealthcare
₹471.95
+5.15 (+1.10%) · EOD 2026-11-20

Our verdict

Buy

Valuation (80/100) does the heavy lifting; momentum (12/100) is the drag.

Fair valueHealth A
Quality 79Momentum 12Value 80Trend 55The Spark ↓

Our fair value

Undervalued by 45%
₹683.87up 44.90%
Price ₹472Range ₹236 – ₹845

Buy-below (20% margin of safety): ₹547.09

The bottom line

TickerMagic rates Vimta Labs Limited a Buy, scoring 61/100 on our blended model. At ₹471.95 it trades below our blended DCF and relative-multiples fair value of ₹683.87, about 45% upside to that estimate — we read it as undervalued by 45%. On 32.4x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 29% below its 52-week high of ₹661.75 and 24% above the low of ₹379.3. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. It clears 9 of 11 investability checks, with durability 79, valuation 59 and momentum 12 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹683.87up 44.90%
Undervalued by 45%
Price ₹471.95Range ₹235.98–₹845.48
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹547.09.

1-year price

EOD · 2026-11-20
1D
up 1.10%
1W
down 6.66%
1M
down 6.49%
3M
down 24.03%
6M
up 4.54%
1Y
—

52-week range

-28.68% from the 52-week high.

Trend check
Below 50-DMA₹546Below 200-DMA₹521

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Buy61
A
Financial health 100/100
Altman Z 15.74 · Safe zone

Piotroski F-score 7/9 — quality of earnings & balance sheet.

Our scores

Durability79
Valuation59
Momentum12

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 9 of 11 checks
Each check screens one fundamentals, valuation or trend signal.
  • No data: ROE above 15%
  • Pass: Low debt (D/E < 0.5): 0.01x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 12%
  • Pass: Earnings growing: 11%
  • Pass: Net margin ≥ 10%: 18.9%
  • No data: Current ratio > 1.5
  • Pass: Below our fair value
  • Pass: Margin of safety ≥ 20%
  • Fail: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 15.74
  • Pass: Piotroski ≥ 7: 7/9

Shareholding

  • Promoter65.9%
  • Institutions4.3%
  • Public & other29.8%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹2,549 Cr
P/E ratio
32.4
P/B ratio
5.58
EPS (TTM)
₹17.63
ROE
—
Debt / Equity
0.01x
Profit margin
18.9%
Free cash flow
₹47 Cr
52-week high
₹661.75
-28.68% from high
52-week low
₹379.3
Dividend yield
0.3%
Beta
-0.18
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • Healthy profit margin (18.9%).
  • Financially solid — Altman Z 15.74.
  • High Piotroski quality score (7/9).

Opportunities

  • Trades ~45% below our estimated fair value.

Bear case

Weaknesses

  • Price below its 200-day moving average (downtrend).

About Vimta Labs Limited

Vimta Labs Limited provides contract research and testing services to biopharmaceutical, medical device, agrochemical, and specialty chemical companies across India and international markets. The company offers preclinical and clinical research, drug discovery and development services, drug life cycle management support, and analytical services for the pharmaceutical sector, alongside preclinical testing for medical device manufacturers.

Vimta Labs Limited — frequently asked questions

Is Vimta Labs Limited a buy, hold or sell?

TickerMagic currently rates Vimta Labs Limited (VIMTALABS) a Buy, based on a blended score of 61/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Vimta Labs Limited's fair value?

Our blended DCF and relative-valuation model estimates Vimta Labs Limited's fair value at about ₹683.87, versus a current price of ₹471.95 — roughly 45% upside. On that basis the stock looks undervalued by 45%.

Is Vimta Labs Limited financially healthy?

Vimta Labs Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.

How has Vimta Labs Limited's share price performed?

Vimta Labs Limited is down 24% over three months, and last traded at ₹471.95. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.